I’ll be tweeting when I can from the International Menopause Society Congress.
#IMS2022
#IMS2022
Starting with the meeting before the meeting.
The Council of Affiliated Menopause Societies.
Societies from around the world connecting and collaborating.
Welcome from IMS President Steven Goldstein.
#IMS2022
The Council of Affiliated Menopause Societies.
Societies from around the world connecting and collaborating.
Welcome from IMS President Steven Goldstein.
#IMS2022
New CAMS chair Dr Duru Shah pointing out that the number of women over 60 is expected to double by 2050.
UN priority is to reduce health inequities and ageism and promote healthy aging.
UN priority is to reduce health inequities and ageism and promote healthy aging.
Hearing from menopause practitioners in low and medium income countries. Menopause often neglected due to lack of resources and prioritization of other issues.
Menopause care considered a luxury and patients struggling to access care and afford MHT when needed.
IMS President-elect Prof Nick Panay talking about the importance of health policies prioritizing womens’s health
#IMS2022
#IMS2022
No speaker photos because I’m sitting in the wrong spot.
Packed auditorium. 1600 participants, 76 countries. Some online. Welcome from Prof Steven Goldstein.
Packed auditorium. 1600 participants, 76 countries. Some online. Welcome from Prof Steven Goldstein.
First plenary lecture by Australian Prof Susan Davis.
Testosterone for women, certainties and uncertainties.
#IMS2022
Testosterone for women, certainties and uncertainties.
#IMS2022
Testosterone recognized as a female hormone in 1943.
First used in women in 1950 for vulvovaginal atrophy.
Treatment for systemic menopausal symptoms started in 1980s.
First used in women in 1950 for vulvovaginal atrophy.
Treatment for systemic menopausal symptoms started in 1980s.
A suggestion of benefit for sexual function for transdermal T in 1990s.
But is ‘female androgen deficiency’ really an appropriate term?
But is ‘female androgen deficiency’ really an appropriate term?
Immunoassays for T unreliable at lower levels in women.
Liquid chromatography mass spec more reliable.
Using LCMS T levels drop by 25% from 18-39 yrs.
But T levels in elderly women are similar to young women.
Liquid chromatography mass spec more reliable.
Using LCMS T levels drop by 25% from 18-39 yrs.
But T levels in elderly women are similar to young women.
There is limited correlation of endogenous T levels and sexual function.
Cardiovascular disease. High T in post menopausal women not associated with increased CV risk.
Low T appears to be associated with higher risk.
Observational data. Subject to confounding factors.
Low T appears to be associated with higher risk.
Observational data. Subject to confounding factors.
What about testosterone therapy in women?
Current evidence is for use in hypoactive sexual desire disorder.
No benefit in depression.
Current evidence is for use in hypoactive sexual desire disorder.
No benefit in depression.
Insufficient data on long term safety.
There is no biochemical diagnosis for ‘androgen deficiency syndrome’.
There is no biochemical diagnosis for ‘androgen deficiency syndrome’.
Research needed in
-premenopausal women
-POI
-osteosarcopaenia
-cognition
-CVD
-VVA (some evidence of benefit here).
#IMS2022
-premenopausal women
-POI
-osteosarcopaenia
-cognition
-CVD
-VVA (some evidence of benefit here).
#IMS2022
• • •
Missing some Tweet in this thread? You can try to
force a refresh
